PENUMBRA

Penumbra Introduces Next Generation REAL® y-Series™, Expanding Virtual Reality Healthcare Platform

Retrieved on: 
Thursday, March 31, 2022
Technology, Medical Devices, Seniors, Hospitals, Software, Physical Therapy, Hardware, Health, Consumer, LinkedIn, VR, Cognition, Failure, Investment, Multimedia, NYSE, Culture, SEC, ADL, Conference, Hospital, Occupational therapy, REAL, Health, U.S. Securities and Exchange Commission, American Occupational Therapy Foundation, Virtual reality, Software, Technology, Safety, Twitter, COVID-19, Y, Frasier, Nature, Annual report, Patient, Security (finance), Healthcare, Medical device, Pharmaceutical industry, THE REAL IMMERSIVE SYSTEM PORTFOLIO, PENUMBRA

(NYSE: PEN), a global healthcare company focused on innovative therapies, today introduced the REAL Immersive System y-Series, expanding its comprehensive virtual reality-based healthcare platform with significantly more activities and experiences now available to help improve patient care, including clinical rehabilitation therapy.

Key Points: 
  • (NYSE: PEN), a global healthcare company focused on innovative therapies, today introduced the REAL Immersive System y-Series, expanding its comprehensive virtual reality-based healthcare platform with significantly more activities and experiences now available to help improve patient care, including clinical rehabilitation therapy.
  • View the full release here: https://www.businesswire.com/news/home/20220331005390/en/
    Penumbra, Inc. introduces the REAL Immersive System y-Series, expanding its comprehensive virtual reality-based healthcare platform with significantly more activities and experiences now available to help improve patient care, including clinical rehabilitation therapy.
  • Our next generation REAL y-Series represents our next step in fulfilling our vision for a healthcare-specific platform.
  • Penumbras REAL Immersive System is a platform of products that leverages virtual reality to deliver engaging, immersive healthcare designed to promote better health, including furthering functional skills, cognition and stress management.

New Data Demonstrates Safety and Performance of Continuous Aspiration Thrombectomy with Penumbra’s Indigo® System CAT™ RX Catheter in High-Risk Patients with Acute Coronary Syndrome

Retrieved on: 
Friday, November 5, 2021
Cardiology, Biotechnology, Surgery, General Health, Health, Medical Devices, Clinical Trials, Other Health, Myocardial infarction, Columbia University Irving Medical Center, TIMI, Safety, TCT, Șaeș, CAT, Medicine, Culture, Perfusion, MBG, Heart, Security (finance), Thrombus, Technology, Failure, Trial of the century, Investment, MACE, Use, COVID-19, Multimedia, Stroke, Annual report, PCI, Twitter, Contraindication, Percutaneous coronary intervention, Incidence, Manatee Memorial Hospital, Hospital, U.S. Securities and Exchange Commission, NYHA, Columbia University, LinkedIn, SEC, Nature, NYSE, Physician, Time, Joe Byrd (Cherokee Nation Principal Chief), Patient, Reperfusion, Acute coronary syndrome, Cardiogenic shock, Pharmaceutical industry, Risk management, the CHEETAH Study, Penumbra, THE CHEETAH STUDY, PENUMBRA

After only one pass with Penumbras CAT RX, we were pleased to see restoration of blood flow and perfusion when used upfront in acute coronary syndrome interventions.

Key Points: 
  • After only one pass with Penumbras CAT RX, we were pleased to see restoration of blood flow and perfusion when used upfront in acute coronary syndrome interventions.
  • The CHEETAH clinical study enrolled 400 patients with high thrombus burden who were treated with continuous mechanical aspiration thrombectomy with CAT RX prior to PCI.
  • As part of the Indigo Aspiration System, the Indigo CAT RX Aspiration Catheters and Indigo Separator 4 are indicated for the removal of fresh, soft emboli and thrombi from vessels in the coronary and peripheral vasculature.
  • The CHEETAH study suggests that CAT RX power aspiration is both safe and effective in a high-risk coronary patient population.

Penumbra Introduces REAL® i-Series™, Expanding REAL Immersive System to Support Broad Range of Care Providers and Mental Health Professionals

Retrieved on: 
Tuesday, August 10, 2021
Hardware, Other Health, Technology, Audio, Video, Physical Therapy, Managed Care, Mental Health, General Health, Medical Devices, Seniors, Hospitals, Other Technology, Software, Consumer, Health, Connect, Loneliness, Therapy, Health, Failure, Nature, Company, LinkedIn, Patient, Annual report, Pain, U.S. Securities and Exchange Commission, Hospital, High-functioning autism, Technology, REAL, Security (finance), NYSE, Serene, COVID-19, Relaxation, Twitter, Virtual reality, Multimedia, VR, Depression, SEC, Webcast, Culture, Ascending limb of loop of Henle, Cognition, Communication, Video game console, Medical device, the REAL Immersive System Portfolio, Penumbra, THE REAL IMMERSIVE SYSTEM PORTFOLIO, PENUMBRA

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the introduction of the REAL Immersive System i-Series, offering engaging, immersive, gaze-based experiences and activities to care providers and mental health professionals.

Key Points: 
  • Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the introduction of the REAL Immersive System i-Series, offering engaging, immersive, gaze-based experiences and activities to care providers and mental health professionals.
  • View the full release here: https://www.businesswire.com/news/home/20210810005398/en/
    REAL Immersive System i-Series offers engaging, immersive, gaze-based experiences and activities to a broad range of care providers and mental health professionals.
  • (Photo: Business Wire)
    REAL i-Series is designed for a broad range of care providers and mental health professionals.
  • Penumbra, the Penumbra P logo, REAL System, REAL i-Series, REAL Connect and Serene Lake are trademarks of Penumbra, Inc. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn .

Penumbra Receives FDA Clearance for RED 62 Reperfusion Catheter, Enabling Physicians to Address Broad Range of Stroke Patients

Retrieved on: 
Wednesday, June 23, 2021
Medical devices, Surgery, Hospitals, FDA, Public relations, Investor relations, Communications, Cardiology, Radiology, General Health, Health, Medicine, Cardiovascular system, Clinical medicine, Thrombectomy, Penumbra, Ischemia, Stroke, Thrombus, Aspiration, the Penumbra System, Penumbra, THE PENUMBRA SYSTEM, PENUMBRA

RED 62 is designed to navigate complex distal vessel anatomy and deliver powerful aspiration, together with Penumbra ENGINE, for the removal of blood clots in acute ischemic stroke patients with large vessel occlusions.

Key Points: 
  • RED 62 is designed to navigate complex distal vessel anatomy and deliver powerful aspiration, together with Penumbra ENGINE, for the removal of blood clots in acute ischemic stroke patients with large vessel occlusions.
  • The performance and length of RED 62 enable me to address a broader group of patients using aspiration thrombectomy to remove blood clots and improve my patients health outcomes.
  • With the continued success of aspiration thrombectomy, physicians asked us to address navigation in more challenging distal vessels.
  • Penumbra, the Penumbra P logo, Penumbra ENGINE, RED, and 3D Revascularization Device are trademarks of Penumbra, Inc. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn .